{
"info": {
"nct_id": "NCT03274882",
"official_title": "Open-label Multicentre Confirmatory Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapies",
"inclusion_criteria": "* Male or female aged ≥18 years of age\n* Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum\n* Has received at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer (including fluoropyrimidines, irinotecan and oxaliplatin and, if accessible, an anti-VEGF monoclonal antibody and at least one of the anti-EGFR monoclonal antibodies for RAS wild-type patients (if RAS mutation status was evaluated)) and was refractory or intolerant to those chemotherapies\n* Has Eastern Cooperative Group (ECOG) performance status of 0 or 1\n* Has at least one measurable metastatic lesion(s)\n* Has adequate organ function\n* Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of birth control during the study and for 6 months after the discontinuation of study medication\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Pregnancy, breastfeeding\n* Participation in another interventional study within 4 weeks prior to inclusion; participation in non-interventional registries or epidemiological studies is allowed\n* Has previously received S95005 or history of allergic reaction attributed to compounds of similar composition to S95005\n* Has a serious illness or medical condition(s) as described in the protocol\n* Has had certain other recent treatment e.g. major surgery, field radiation, anticancer therapy, within the specified time frames prior to inclusion\n* Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 attributed to any prior therapies.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Has at least one measurable metastatic lesion(s)",
"criterions": [
{
"exact_snippets": "at least one measurable metastatic lesion(s)",
"criterion": "metastatic lesion",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "N/A"
}
}
},
{
"exact_snippets": "at least one measurable metastatic lesion(s)",
"criterion": "metastatic lesion",
"requirement": {
"requirement_type": "measurability",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "at least one measurable metastatic lesion(s)",
"criterion": "metastatic lesion",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "N/A"
}
}
},
{
"exact_snippets": "at least one measurable metastatic lesion(s)",
"criterion": "metastatic lesion",
"requirement": {
"requirement_type": "measurability",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Has adequate organ function",
"criterions": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of birth control during the study and for 6 months after the discontinuation of study medication",
"criterions": [
{
"exact_snippets": "Female participants of childbearing potential",
"criterion": "female participants",
"requirement": {
"requirement_type": "childbearing potential",
"expected_value": true
}
},
{
"exact_snippets": "male participants with partners of childbearing potential",
"criterion": "male participants",
"requirement": {
"requirement_type": "partner's childbearing potential",
"expected_value": true
}
},
{
"exact_snippets": "must agree to use a highly effective method of birth control during the study and for 6 months after the discontinuation of study medication",
"criterion": "birth control",
"requirement": {
"requirement_type": "usage",
"expected_value": "highly effective method during the study and for 6 months after discontinuation"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"exact_snippets": "Female participants of childbearing potential",
"criterion": "female participants",
"requirement": {
"requirement_type": "childbearing potential",
"expected_value": true
}
},
{
"exact_snippets": "male participants with partners of childbearing potential",
"criterion": "male participants",
"requirement": {
"requirement_type": "partner's childbearing potential",
"expected_value": true
}
}
]
},
{
"exact_snippets": "must agree to use a highly effective method of birth control during the study and for 6 months after the discontinuation of study medication",
"criterion": "birth control",
"requirement": {
"requirement_type": "usage",
"expected_value": "highly effective method during the study and for 6 months after discontinuation"
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Pregnancy, breastfeeding",
"criterions": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
}
},
{
"identified_line": {
"line": "* Participation in another interventional study within 4 weeks prior to inclusion; participation in non-interventional registries or epidemiological studies is allowed",
"criterions": [
{
"exact_snippets": "Participation in another interventional study within 4 weeks prior to inclusion",
"criterion": "participation in another interventional study",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "participation in non-interventional registries or epidemiological studies is allowed",
"criterion": "participation in non-interventional registries or epidemiological studies",
"requirement": {
"requirement_type": "allowance",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"not_criteria": {
"exact_snippets": "Participation in another interventional study within 4 weeks prior to inclusion",
"criterion": "participation in another interventional study",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
}
},
{
"exact_snippets": "participation in non-interventional registries or epidemiological studies is allowed",
"criterion": "participation in non-interventional registries or epidemiological studies",
"requirement": {
"requirement_type": "allowance",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Has previously received S95005 or history of allergic reaction attributed to compounds of similar composition to S95005",
"criterions": [
{
"exact_snippets": "Has previously received S95005",
"criterion": "previous treatment with S95005",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "history of allergic reaction attributed to compounds of similar composition to S95005",
"criterion": "allergic reaction to compounds similar to S95005",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Has previously received S95005",
"criterion": "previous treatment with S95005",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "history of allergic reaction attributed to compounds of similar composition to S95005",
"criterion": "allergic reaction to compounds similar to S95005",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Has a serious illness or medical condition(s) as described in the protocol",
"criterions": [
{
"exact_snippets": "Has a serious illness or medical condition(s)",
"criterion": "serious illness or medical condition",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Has a serious illness or medical condition(s)",
"criterion": "serious illness or medical condition",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* Has had certain other recent treatment e.g. major surgery, field radiation, anticancer therapy, within the specified time frames prior to inclusion",
"criterions": [
{
"exact_snippets": "Has had certain other recent treatment e.g. major surgery",
"criterion": "recent major surgery",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Has had certain other recent treatment e.g. ... field radiation",
"criterion": "recent field radiation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Has had certain other recent treatment e.g. ... anticancer therapy",
"criterion": "recent anticancer therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Has had certain other recent treatment e.g. major surgery",
"criterion": "recent major surgery",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Has had certain other recent treatment e.g. ... field radiation",
"criterion": "recent field radiation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Has had certain other recent treatment e.g. ... anticancer therapy",
"criterion": "recent anticancer therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 attributed to any prior therapies.",
"criterions": [
{
"exact_snippets": "unresolved toxicity ... greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2",
"criterion": "unresolved toxicity",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "CTCAE Grade"
}
}
},
{
"exact_snippets": "attributed to any prior therapies",
"criterion": "attribution to prior therapies",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "unresolved toxicity ... greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2",
"criterion": "unresolved toxicity",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "CTCAE Grade"
}
}
},
{
"exact_snippets": "attributed to any prior therapies",
"criterion": "attribution to prior therapies",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Male or female aged ≥18 years of age",
"criterions": [
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"male",
"female"
]
}
},
{
"exact_snippets": "aged ≥18 years of age",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirement": {
"requirement_type": "presence",
"expected_value": "male"
}
},
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirement": {
"requirement_type": "presence",
"expected_value": "female"
}
}
]
},
{
"exact_snippets": "aged ≥18 years of age",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum",
"criterions": [
{
"exact_snippets": "definitive histologically or cytologically confirmed adenocarcinoma",
"criterion": "adenocarcinoma",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
},
{
"exact_snippets": "adenocarcinoma of the colon or rectum",
"criterion": "location of adenocarcinoma",
"requirement": {
"requirement_type": "location",
"expected_value": [
"colon",
"rectum"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "definitive histologically or cytologically confirmed adenocarcinoma",
"criterion": "adenocarcinoma",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically"
]
}
},
{
"exact_snippets": "definitive histologically or cytologically confirmed adenocarcinoma",
"criterion": "adenocarcinoma",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"cytologically"
]
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "adenocarcinoma of the colon or rectum",
"criterion": "location of adenocarcinoma",
"requirement": {
"requirement_type": "location",
"expected_value": "colon"
}
},
{
"exact_snippets": "adenocarcinoma of the colon or rectum",
"criterion": "location of adenocarcinoma",
"requirement": {
"requirement_type": "location",
"expected_value": "rectum"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Has received at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer (including fluoropyrimidines, irinotecan and oxaliplatin and, if accessible, an anti-VEGF monoclonal antibody and at least one of the anti-EGFR monoclonal antibodies for RAS wild-type patients (if RAS mutation status was evaluated)) and was refractory or intolerant to those chemotherapies",
"criterions": [
{
"exact_snippets": "Has received at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer",
"criterion": "prior regimens of standard chemotherapies",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "regimens"
}
}
},
{
"exact_snippets": "including fluoropyrimidines, irinotecan and oxaliplatin",
"criterion": "types of chemotherapies received",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"fluoropyrimidines",
"irinotecan",
"oxaliplatin"
]
}
},
{
"exact_snippets": "if accessible, an anti-VEGF monoclonal antibody",
"criterion": "anti-VEGF monoclonal antibody",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "at least one of the anti-EGFR monoclonal antibodies for RAS wild-type patients",
"criterion": "anti-EGFR monoclonal antibodies",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "if RAS mutation status was evaluated",
"criterion": "RAS mutation status evaluation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "was refractory or intolerant to those chemotherapies",
"criterion": "refractory or intolerant to chemotherapies",
"requirement": {
"requirement_type": "condition",
"expected_value": "refractory or intolerant"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Has Eastern Cooperative Group (ECOG) performance status of 0 or 1",
"criterions": [
{
"exact_snippets": "Has Eastern Cooperative Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Has Eastern Cooperative Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "0"
}
},
{
"exact_snippets": "Has Eastern Cooperative Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "1"
}
}
]
}
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}